Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311…
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil,…
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil,…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Tim Blauwkamp, Ph.D., Chief Scientific Officer and co-founder…
In this edition of The Onco’Zine Brief, Peter Hofland, Ph.D., talks with Vince McRuiz and Margo Shoup, MD, FACS.Margo Shoup…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Armon Sharei, Ph.D. Chief Executive Officer of SQZ…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Terri Conneran, a lung cancer survivor and patient advocate.…
In this episode of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS) held December 10…
In this edition of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS), held December 10…
Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
In this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Dre Benedetta Guani – University Hospital of Lausanne discusses Histopathologic validation of the sentinel node technique in early-stage cervical cancerASCOhttps://meetinglibrary.asco.org/record/187420/abstract
Dre Benedetta Guani – University Hospital of Lausanne discusses Histopathologic validation of the sentinel node technique in early-stage cervical cancerASCOhttps://meetinglibrary.asco.org/record/187420/abstract
Liv Johannessen, P.h.D.Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of…
Liv Johannessen, P.h.D. Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models…
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the…
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the…
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the…
Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial…
Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Raj Malik, MD – G1 Therapeutics discusses G1 Therapeutics to present data showing myelopreservation benefits of Trilaciclib in patients with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation…
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation…
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh…
Total glossectomy is a surgical option for patients with advanced (stage IV cancers) or recurrent tongue cancer. Advanced cancer of…
Buccal cancer involving masticator space grows rapidly and penetrates well with a high recurrence rate due its aggressive nature. The…
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Juan Carlos Varela, MD – AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients
Juan Carlos Varela, MD AdventHealth discusses AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients.
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune…
Nicolas Poirier, Ph.D. – OSE Immunotherapeutics – discusses – Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
David A. Reardon, MD Dana-Farber Cancer Institute discusses What is the rationale in combining these agents together? – INO-5401 and…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results…
Christoph Röllig, MD discusses For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait
Andrea Enzinger, MD Dana-Farber Cancer Institute discusses US trends and racial/ethnic disparities in opioid access among patients with poor prognosis…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of…
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of…
Featuring David Gandara, MD and Johannes Kratz, MD Please visit www.oncocyte.com for more information on DetermaRx  2020 has ushered…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib…
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and…
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and…
Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and…
Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Caron Jacobson, MD of Dana Farber Cancer Institute @DanaFarber discusses the interim analysis of zuma-5 presented at this year’s virtual…
Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant…
Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant…
Lipika Goyal, MD of Massachusetts General Hospital @MassGeneralNews discusses the data for futibatinib in advanced intrahepatic cholangiocarcinoma. Read here:Â https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-for-futibatinib-in-advanced-intrahepatic-cholangiocarcinoma-at-2020-asco-meeting-301068213.html?tc=eml_cleartime
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS…
Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS…
Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food…
Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell…
Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell…
Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term…
Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a…
Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type…
Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer.…
Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer.…
Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for…
Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for…
Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients…
Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal…
Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal…
Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
William Dale, MD @WilliamDale_MD of City of Hope @CityofHope discusses integrated geriatric assessment and treatment (INTEGERATE) in older people with…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1)…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1)…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated…
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated…
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses DARolutamide observationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC)…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage…
Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage…
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic…
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic…
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat…
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat…
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat…
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from…
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from…
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from…
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast…
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast…
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast…
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression…
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression…
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression…
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated…
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated…
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated…
Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for…
Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for…
Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for…
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults…
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults…
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Earn CME: https://www.naccme.com/program/20-hemcovid-7 In this webcast, Drs. Joseph R. Mikhael and Michael J. Satlin discuss new updates on the current…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440)…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440)…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.
Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.
Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell…
Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
Saad Z. Usmani, M.DÂ @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a…
Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety…
Earn CME: https://www.naccme.com/program/20-hemcovid-6 In this webcast, Drs. Joseph R. Mikhael and Jessica K. Altman discuss best practices for addressing current…
Earn CME: https://www.naccme.com/program/20-hemcovid-5 In this webcast, Dr. Joseph R. Mikhael and patient advocate Yelak Biru discuss ways to limit patient…
Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the…
Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the…
Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the…
Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade…
Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and…
Andrew Krivoshik, MD of Astellas @AstellasUS discusses what is net for Astellas.
Andrew Krivoshik, MD of Astellas @AstellasUS discusses the long-term results of the phase III ADMIRAL trial presented at this year’s…
Andrew Krivoshik, MD of Astellas @AstellasUS discusses the importance of the phase III PROSPER trial in the prostate cancer community…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients…
Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for…